• Radiographic progression free survival (PFS) [ Time Frame: Up to 2 years ]
  Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue metastases and Prostate Cancer Working Group 3 criteria for bone metastases. Will be presented with Kaplan-Meier curves, and the median survival with 95% confidence interval (CI) will be calculated. Rates will be reported as percentages with 95% CI.
• Time to response [ Time Frame: Up to 2 years ]
  Will be assessed by RECIST 1.1.
• Overall survival (OS) [ Time Frame: From cycle 1, day 1 to the date of death, assessed up to 2 years ]
  Will be assessed by RECIST 1.1. Will be presented with Kaplan-Meier curves, and the median survival with 95% CI will be calculated. Rates will be reported as percentages with 95% CI.
• Prostate-specific antigen (PSA) response [ Time Frame: Baseline up to 2 years ]
  PSA response will be defined by a > 50% reduction in PSA compared with baseline at any point during treatment.
• Incidence and severity of adverse events (AEs) [ Time Frame: Within 14 days of end of treatment ]
  Will be assessed using version National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Will characterize AEs by type and grade. Safety will be summarized as the severity and frequency of a given AE.

• Radiographic progression free survival (PFS) [ Time Frame: Up to 2 years ]
  Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue metastases and Prostate Cancer Working Group 3 criteria for bone metastases. Will be presented with Kaplan-Meier curves, and the median survival with 95% confidence interval (CI) will be calculated. Rates will be reported as percentages with 95% CI.
• Time to response [ Time Frame: Up to 2 years ]
  Will be assessed by RECIST 1.1.
• Overall survival (OS) [ Time Frame: Up to 2 years ]
  Will be assessed by RECIST 1.1. Will be presented with Kaplan-Meier curves, and the median survival with 95% CI will be calculated. Rates will be reported as percentages with 95% CI.
• Prostate-specific antigen (PSA) response [ Time Frame: Baseline up to 2 years ]
  PSA response will be defined by a > 50% reduction in PSA compared with baseline at any point during treatment.
• Incidence and severity of adverse events (AEs) [ Time Frame: Within 14 days of end of treatment ]
  Will be assessed using version National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Will characterize AEs by type and grade. Safety will be summarized as the severity and frequency of a given AE.

OUTLINE: Patients receive abiraterone acetate orally (PO) once daily (QD) or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

• Castration-Resistant Prostate Carcinoma
• Double-Negative Prostate Carcinoma
• Metastatic Prostate Carcinoma
• Prostate Adenocarcinoma
• Stage IV Prostate Cancer AJCC v8
• Stage IVA Prostate Cancer AJCC v8
• Stage IVB Prostate Cancer AJCC v8

• Drug: Abiraterone Acetate
  Given PO
  Other Names:

  • 154229-18-2
  • 17-(3-Pyridyl)-5
  • 16-androstadien-3beta-acetate
  • Androsta-5,16-dien-3-ol
  • 17-(3-pyridinyl)-
  • acetate (ester)
  • CB7630
  • Yonsa
  • Zytiga
• Drug: Enzalutamide
  Given PO
  Other Names:

  • 915087-33-1
  • ASP9785
  • Benzamide
  • MDV3100
  • Xtandi
• Drug: Erdafitinib
  Given PO
  Other Names:

  • Balversa
  • JNJ-42756493

Inclusion Criteria:

• History of histologically diagnosed prostatic adenocarcinoma
• Participants must have evidence of castration resistant prostate cancer as evidenced by a confirmed rising PSA or radiographic progression (per Prostate Cancer Working Group 3 [PCWG3] criteria) and a castrate serum testosterone level (i.e. =< 50 mg/dL)
• Participants must have previously progressed on abiraterone acetate and/or enzalutamide, with PSA or radiographic progression on the most recent agent per PCWG3 criteria. If the most recent agent received was abiraterone or enzalutamide there should be no washout prior to initiating erdafitinib per protocol
• Measurable disease as defined per RECIST v1.1 criteria
• Subjects must have evidence of double-negative prostate cancer as defined by immunohistochemistry on biopsy. A fresh metastatic biopsy within 8 weeks is preferred; however, any archival tissue showing a DNPC phenotype will be acceptable for determining eligibility. Note: transcript profiling methods for defining DNPC may be accepted per the PI's discretion
• Eastern Cooperative Oncology Group (ECOG) performance status score =< 2
• Hemoglobin >= 8 g/dL (>= 5 mmol/L) (must be without red blood cell [RBC] transfusion within 7 days prior to the laboratory test)
• Platelets >= 75 x 10^9/L
• Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (prior growth factor support is permitted but must be without support in the 7 days prior to the laboratory test)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN for subjects with liver metastases
• Creatinine clearance >= 40 mL/min/1.73 m^2 based upon modified diet in renal disease formula calculation
• Total bilirubin =< 1.5 x ULN; except in subjects with congenital bilirubinemia, such as Gilbert syndrome
• Corrected QT interval (corrected QT interval by Fridericia [QTcF] or QT corrected interval by the Bazett's formula [QTcB]) =< 480 msec based on the average of triplicate assessments performed approximately 5 minutes apart
• Subjects must agree to use acceptable contraception
• Must sign an informed consent form (ICF) (or their legally acceptable representative must sign) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion Criteria:

• Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to randomization
• Active malignancies (i.e., requiring treatment change in the last 24 months) other than malignancy under study (except skin cancers within the last 24 months that is considered completely cured)
• Evidence of predominant small cell or neuroendocrine variant prostate cancer on most recent standard of care metastatic biopsy
• Symptomatic central nervous system (CNS) metastases. Treated CNS metastases will be allowed if these are stable for at least 8 weeks prior to enrollment
• Received prior FGFR inhibitor treatment or if the subject has known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
• Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade
• Has persistent phosphate level > ULN during screening (on 2 consecutive assessments at least 1 week apart, within 14 days of treatment and prior to cycle 1 day 1) and despite medical management

• Has a history of or current uncontrolled cardiovascular disease including:

  • Unstable angina, myocardial infarction, ventricular fibrillation, Torsades de Pointes, cardiac arrest, or known congestive heart failure class III-V within the preceding 3 months; cerebrovascular accident or transient ischemic attack within the preceding 3 months
  • Pulmonary embolism or other VTE (venous thromboembolism) within the preceding 2 months
• Has known active acquired immune deficiency syndrome (AIDS) (human immunodeficiency virus [HIV] infection)
• Hepatitis B infection as defined according to the American Society of Clinical Oncology guidelines. In the event the infection status is unclear, quantitative levels are necessary to determine the infection status. Hepatitis C (anti-hepatitis C virus [HCV] antibody positive or HCV-ribonucleic acid [RNA] quantitation positive) or known to have a history of hepatitis C. If positive, further testing of quantitative levels to rule out positivity is required
• Has not recovered from reversible toxicity of prior anticancer therapy (except toxicities which are not clinically significant such as alopecia, skin discoloration, hot flashes, grade 1 neuropathy, grade 1-2 hearing loss)
• Has impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions
• Major surgery within 2 weeks of the first dose, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study or within 2 weeks after the last dose of study drug administration. (Note: subjects with planned surgical procedures to be conducted under local anesthesia may participate

• Any serious underlying medical condition, such as:

  • Evidence of serious active viral, bacterial, or uncontrolled systemic fungal infection
  • Active autoimmune disease or a documented history of autoimmune disease
  • Psychiatric conditions (e.g., alcohol or drug abuse), dementia, or altered mental status
• Any other issue that would impair the ability of the subject to receive or tolerate the planned treatment at the investigational site, to understand informed consent or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
• Patient, who, in the opinion of their treating physician, requires immediate treatment (e.g. those with extensive liver metastases)

• National Cancer Institute (NCI)
• Janssen Research & Development, LLC